Analyst Price Target is $9.00
▲ +448.78% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Precigen in the last 3 months. The average price target is $9.00, with a high forecast of $14.00 and a low forecast of $6.00. The average price target represents a 448.78% upside from the last price of $1.64.
Current Consensus is
The current consensus among 3 contributing investment analysts is to buy stock in Precigen. This Buy consensus rating has held steady for over two years.
Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.